InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by BREITMEYER JAMES B, Director. Insider active across 3 companies, notably Vaxart, Inc.. Cumulatively, 7 disclosures have been published. Total volume traded: €75k. The latest transaction was filed on 23 April 2026 — Attribution. Regulator: SEC (Form 4). All data is openly available.
Declarations7 total
078,800 shares0
Common Stock
SEC:0001437749-26-014528·
078,800 shares0
Common Stock
SEC:0001437749-26-014528:0·
1,250 shares
Common Stock
SEC:0000899243-22-010312:0·
€37,42625,000 shares@ €1.49750.0% of flow
Common Stock
SEC:0001209191-22-005556:0·
Ideal exit: 24 Oct 2022 (T+270)
€37,42625,000 shares@ €1.497100.0% of flow
Common Stock
SEC:0001209191-22-005556·
Ideal exit: 24 Oct 2022 (T+270)
0128,557 shares0
Common Stock
SEC:0001209191-22-001974·
0128,557 shares0
Common Stock
SEC:0001209191-22-001974:0·
7 of 7 declarations
About BREITMEYER JAMES B
James B. Breitmeyer is the Chief Executive Officer of Vaxart, Inc., Oncternal Therapeutics, Inc., and ZOGENIX, INC. He leads these companies with a focus on innovation and the development of new treatments. His leadership is essential for the growth of these firms.
